Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03617302
Other study ID # 201805720
Secondary ID
Status Active, not recruiting
Phase Early Phase 1
First received
Last updated
Start date November 1, 2018
Est. completion date June 30, 2024

Study information

Verified date May 2023
Source University of Iowa
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study investigates the effect of dietary inorganic nitrate supplementation on 1) large elastic artery stiffness and hemodynamics and 2) cerebrovascular function in middle-aged and older adults. Participants will be randomized to consume either nitrate-containing or nitrate-depleted beetroot juice.


Description:

Reduced nitric oxide bioavailability with aging contributes in part to increased large central artery stiffness and cerebrovascular dysfunction. Large central artery stiffness is a risk factor for cognitive decline mediated in part by the development of cerebrovascular dysfunction. This study will investigate the degree to which improving nitric oxide bioavailability using dietary inorganic nitrate supplementation improves cerebrovascular function through reductions in large central artery stiffness in middle-aged and older adults.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 53
Est. completion date June 30, 2024
Est. primary completion date December 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 79 Years
Eligibility Inclusion Criteria: - Age 50-79 years - Cognitively healthy, having mild cognitive impairment - Able to undergo cardiovascular testing procedures including fasting overnight and holding selected morning medication doses. - Ability to understand and willingness to sign a written informed consent document. - Ability to lie comfortably for up to 90 minutes - Women only: Post-menopausal Exclusion Criteria: - Current or history of cardiovascular disease disease (heart attack, stroke, heart failure, cardiomyopathy or peripheral artery disease, heart angioplasty/stent or bypass surgery, valve replacement, carotid endarterectomy, heart transplant. - Medical history of stroke or other neurological disorder or systemic illness that could potentially affect cognition or brain function (outside of a diagnosis of Mild Cognitive impairment, Alzheimer's Disease) or could affect their safety or comfort while undergoing the imaging or cardiovascular studies. - Subjects with evidence of cardiovascular disease at baseline or during the exercise test (evidence of myocardial infarction, abnormal cardiac arrhythmia, myocardial ischemia, conduction delays, >1mm S-T segment depression or elevation; >3 beat ventricular tachycardia; atrial fibrillation) will be excluded from the study. - Wilson's disease, hemochromatosis - Individuals taking clonidine or other short-acting beta blocker - Resting blood pressure > 200/ 110 mmHg or systolic <90 mmHg - Medical history of chronic major psychiatric or current diagnosis of major psychiatric disease (other than dementia). - Systemic illness or neurological disorder potentially affecting cognition or cerebral blood flow other than mild cognitive impairment - Unable to provide informed consent due to cognitive impairment - Currently taking medications that may affect cerebral blood flow (e.g. papaverine, indomethacin, acetazolamide, etc) or efficacy of beetroot juice (proton pump inhibitors) - Current clinically abnormal thyroid function not adequately regulated by thyroid hormone supplementation or medication. - Allergic to beets - Current tobacco user or history of tobacco use within the past 3 months (cigarettes, cigars, chewing tobacco, hookah, electronic cigarettes) or living with someone who smokes/has smoked in the past 3 months. - Current diagnosis of insulin-dependent diabetes (Type I or insulin dependent Type II) - Current diagnosis of chronic obstructive lung disease, cystic fibrosis, emphysema, chronic bronchitis - History of renal failure, dialysis or kidney transplant - Current diagnosis or history of liver disease or HIV/AIDS, or cancer (other than non-melanoma skin cancers). - Current diagnosis or history of rheumatoid arthritis, systemic lupus erythematosus, Wegener's granulomatosis - Vulnerable populations (prisoners, etc) will not be eligible. - Unwillingness to wash out from a vitamin or dietary supplement regime prior to enrollment and maintain throughout the duration of the study. - Inability to comply with experimental instructions. - Uncontrolled intercurrent illness that would limit compliance with study requirements per investigator. - Inability to fast or hold morning medications doses until after testing is complete. - Hormone replacement use within the past 6 months - Currently enrolled in another study using an study medication, supplement, device or intervention.

Study Design


Intervention

Drug:
Experimental: Nitrate-containing
Experimental
Placebo: Nitrate-depleted
Placebo

Locations

Country Name City State
United States University of Iowa Iowa City Iowa

Sponsors (2)

Lead Sponsor Collaborator
Gary L. Pierce University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acute change in carotid artery stiffness Common carotid artery stiffness measured by ultrasonography and applanation tonometry. 2-hours
Primary Acute change in cerebral blood flow Large cerebral artery blood flow will be measured using 4-Dimensional (4D) phase contrast vastly undersampled isotropic projection imaging (pcVIPR) magnetic resonance imaging (MRI). 2-hours
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A